Patents by Inventor Julie Bouckaert

Julie Bouckaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10632135
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AUVERGNE, UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE 1, UNIVERSITE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Julie Bouckaert, Sebastien Gouin, Adeline Sivignon, Arlette Darfeuille-Michaud, Rostyslav Bilyy, Dimitri Alvarez-Dorta, Nao Yamakawa, Tetiana Dumych
  • Patent number: 10543223
    Abstract: The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X? represents OH or X and X? taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 28, 2020
    Assignees: ENTEROME, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLERMONT AUVERGNE, UNIVERSITE DE NANTES
    Inventors: Sebastien Gouin, Thibault Chalopin, Julie Bouckaert, Nicolas Barnich, Adeline Sivignon, Dimitri Alexander Alvarez-Dorta, Francois Bellamy
  • Publication number: 20190374559
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 12, 2019
    Inventors: Julie BOUCKAERT, Sebastien GOUIN, Adeline SIVIGNON, Arlette DARFEUILLE-MICHAUD, Rostyslav BILYY, Dimitri ALVAREZ-DORTA, Nao YAMAKAWA, Tetiana DUMYCH
  • Patent number: 10485811
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 26, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AUVERGNE, UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE 1, UNIVERSITE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Julie Bouckaert, Sebastien Gouin, Adeline Sivignon, Arlette Darfeuille-Michaud, Rostyslav Bilyy, Dimitri Alvarez-Dorta, Nao Yamakawa, Tetiana Dumych
  • Patent number: 10273313
    Abstract: The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia coli infections.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: April 30, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE DE PICARDIE JULES VERNE, UNIVERSITE LILLE 1-SCIENCES ET TECHNOLOGIES, UNIVERSITE D'AUVERGNE
    Inventors: Julie Bouckaert, Sebastien Gouin, David Deniaud, Rostyslav Bilyy, Tetiana Dumych, Adeline Sivignon, Arlette Darfeuille-Michaud
  • Publication number: 20180235991
    Abstract: The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X? represents OH or X and X? taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 23, 2018
    Inventors: Sebastien GOUIN, Thibault CHALOPIN, Julie BOUCKAERT, Nicolas BARNICH, Adeline SIVIGNON, Dimitri Alexander ALVAREZ-DORTA, Francois BELLAMY
  • Publication number: 20160340445
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 24, 2016
    Inventors: Julie BOUCKAERT, Sebastien GOUIN, Adeline SIVIGNON, Arlette DARFEUILLE-MICHAUD (Deceased), Rostyslav BILYY, Dimitri ALVAREZ-DORTA, Nao YAMAKAWA, Tetiana DUMYCH
  • Publication number: 20150210781
    Abstract: The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia Coli infections.
    Type: Application
    Filed: July 24, 2013
    Publication date: July 30, 2015
    Inventors: Julie Bouckaert, Sebastien Gouin, David Deniaud, Rostyslav Bilyy, Tetiana Dumych, Adeline Sivignon, Arlette Darfeuille-Michaud
  • Publication number: 20080171706
    Abstract: The present invention provides compounds and compositions capable of inhibiting the attachment of Gram-negative bacteria on a host epithelium.
    Type: Application
    Filed: March 23, 2005
    Publication date: July 17, 2008
    Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW
    Inventors: Jenny Berglund, Julie Bouckaert, Henri De Greve, Stefan Knight
  • Publication number: 20030199071
    Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections.
    Type: Application
    Filed: December 10, 2001
    Publication date: October 23, 2003
    Inventors: Solomon Langermann, Scott J. Hultgren, Chia-Suei Hung, Julie Bouckaert